Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05970913
PET-CT Predicting Lymph Nodes Metastasis
Overview
This study is a single-center prospective clinical study that aims to evaluate the predictive value of preoperative 18F-FDG-PET-CT and 18F-FAPI-PET/CT for lymph node metastasis in patients with non-small cell lung cancer. The final pathological results were used to assess the predictive value of PET-CT for lymph node metastasis.
Sponsor
Fudan University
ClinicalTrials.gov
NCT05970913Drug / Compound
FAPI
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- FAP
Ligand Class: Small Molecules
FDG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Glucose Transport
Ligand Class: Small Molecules
Eligibility
Inclusion
- No history of malignant tumors.
- No prior radiotherapy or chemotherapy for initial treatment.
- Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion.
- Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.
- Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1.
Exclusion
- History of malignant tumors.
- Received neoadjuvant therapy.
- Pleural dissemination observed during surgery.
- Locally advanced or distant metastasis.
- Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).
Share your feedback
Help us improve your experience